Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: A Wisconsin Oncology Network trial

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 613-618

  Njiaju, U O ^a,b   Tevaarwerk, A J ^a,b   Kim, K ^a,b   Chang, J E ^a,b   Hansen, R M ^c   Champeny, T L ^a,b   Traynor, A M ^a,b   Meadows, S ^a,b   Van Ummersen, L ^a,b   Powers, K ^b   Stewart, J A ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Oconomowoc Memorial Hospital   (United States)

Author keywords

Breast cancer; Capecitabine; Metastatic; Neuropathy; Oxaliplatin; XELOX

Indexed keywords

CAPECITABINE; NAVELBINE; OXALIPLATIN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LOW DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO PROGRESSION; TREATMENT OUTCOME; VOMITING; ADOLESCENT; BREAST TUMOR; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875832981     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2044-2     Document Type: Article

References (23)

1. DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics. CA Cancer J Clin 61(6):409-418. doi: 10.3322/caac.20134
2. Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C (2003) Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol 14(4):537-542 (Pubitemid 41295079)
3. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12(9):1247-1254 (Pubitemid 32994752)
4. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R (2005) Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23(10):2155-2161. doi: 10.1200/JCO.2005.02.167 (Pubitemid 46218707)
5. Jung SH, Lee T, Kim K, George SL (2004) Admissible two-stage designs for phase II cancer clinical trials. Stat Med 23(4):561-569. doi: 10.1002/sim.1600 (Pubitemid 38208184)
6. Zamora P AdMM, Calvo L, Jara C, Virizuela JA, Yubero A, Chacon JI, Mira J, Gonzalez Baron M (2005) Capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC). J Clin Oncol, vol 23 (June 1 supplement) (843)
7. Piccart MJ, Raymond E, Aapro M, Eisenhauer EA, Cvitkovic E (1995) Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer 31A(Suppl 7):S1-10
8. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M (2002) Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 20(10):2551-2558 (Pubitemid 34525743)
9. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel. Biochem Pharmacol 52(12):1855-1865 (Pubitemid 26419675)
10. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82(12):1046-1050 (Pubitemid 20204976)
11. Delpeuch A, Leveque D, Rob L, Bergerat JP (2011) Off-label use of oxaliplatin in patients with metastatic breast cancer. Anticancer Res 31(5):1765-1767
12. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485-493 (Pubitemid 29075232)
13. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86(9):1367-1372. doi: 10.1038/sj.bjc.6600261 (Pubitemid 34548055)
14. Polyzos A, Gogas H, Markopoulos C, Tsavaris N, Papadopoulos O, Polyzos K, Giannopoulos A (2009) Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res 29(7):2851-2856
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3):205-216
16. Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21(7):1307-1312 (Pubitemid 46606408)
17. Institute NC (2006) Common toxicity criteria for adverse events v 3.0 (CTCAE). http://ctep.cancer.gov. Accessed 10 Feb 2012
18. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28(20):3256-3263. doi: 10.1200/JCO.2009.24.4244
19. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22(11):2084-2091. doi: 10.1200/JCO.2004.11.069 (Pubitemid 41095141)
20. Comella P, Massidda B, Palmeri S, Farris A, Lucia LD, Natale D, Maiorino L, Tafuto S, Cataldis GD, Casaretti R (2005) Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy cooperative oncology group phase II study. Cancer Chemother Pharmacol 56(5):481-486. doi: 10.1007/s00280-005-1003-6 (Pubitemid 41549149)
21. Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP (2012) A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy 58(1):1-7. doi: 10.1159/000335585
22. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25(10):1247-1254. doi: 10.1200/JCO.2006.08.1844 (Pubitemid 46640571)
23. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12(10):3050-3056. doi: 10.1158/1078-0432.CCR-05-2076 (Pubitemid 43837350)